Adamis Pharmaceuticals Co... (ADMP)
NASDAQ: ADMP
· Real-Time Price · USD
0.78
0.01 (1.50%)
At close: Sep 07, 2023, 9:59 PM
Adamis Pharmaceuticals Revenue Breakdown
| Period Ending | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
|---|---|---|---|---|---|
| Compounded Pharmaceuticals Revenue | 2.74M | 2.78M | 2.96M | 3.43M | 3.2M |
| Compounded Pharmaceuticals Revenue Growth | -1.44% | -6.14% | -13.84% | +7.10% | n/a |
| Manufactured Product, Other Revenue | 1.28M | 1.33M | 679.79K | 868.08K | 721.43K |
| Manufactured Product, Other Revenue Growth | -4.29% | +96.04% | -21.69% | +20.33% | n/a |
| Non-Sterile Product Revenue | 1.08M | 1.15M | 1.04M | 1.19M | 1.22M |
| Non-Sterile Product Revenue Growth | -6.06% | +10.60% | -12.73% | -2.46% | n/a |
| Sterile Product Revenue | 1.65M | 1.63M | 1.92M | 2.24M | 1.98M |
| Sterile Product Revenue Growth | +1.83% | -15.23% | -14.42% | +13.00% | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 2.52M | 4.03M | 4.78M | 3.15M | 2.51M | 4.21M | 3.38M | 2.9M | 4.79M | 7.13M | 5.92M | 13.08M | 5.79M | 5.65M | 6.05M | 4.97M | 5.3M | 7M | 8.02M | 6.58M | 6.53M | 6.36M | 6.47M | 5.84M | 5.75M | 5.66M | 5.57M | 4.59M | 5.34M | 4.58M | 2.62M | 1.83M | 2.13M | 2.26M | 2.79M |
| Selling, General, and Administrative Revenue Growth | -37.59% | -15.66% | +51.77% | +25.62% | -40.37% | +24.34% | +16.78% | -39.59% | -32.77% | +20.48% | -54.74% | +125.74% | +2.49% | -6.63% | +21.92% | -6.31% | -24.29% | -12.73% | +21.97% | +0.64% | +2.70% | -1.71% | +10.78% | +1.68% | +1.64% | +1.48% | +21.34% | -13.92% | +16.41% | +75.17% | +43.22% | -14.04% | -6.05% | -19.03% | n/a |
| Research and Development Revenue | 418.52K | 376.96K | 1.31M | 859.85K | 1.98M | 3.32M | 4.22M | 2.2M | 4.62M | 2.23M | 2.26M | 1.46M | 1.7M | 3.09M | 2.04M | 2.01M | 3.32M | 2.85M | 2.2M | 7.8M | 3.91M | 4.84M | 2.25M | 3.58M | 1.25M | 1.19M | 1.51M | 1.37M | 1.49M | 3.43M | 3.4M | 1.04M | 1.18M | 1.27M | 1.36M |
| Research and Development Revenue Growth | +11.03% | -71.24% | +52.41% | -56.53% | -40.44% | -21.34% | +92.26% | -52.47% | +106.92% | -1.26% | +55.01% | -14.16% | -44.93% | +51.51% | +1.08% | -39.28% | +16.62% | +29.56% | -71.84% | +99.59% | -19.17% | +115.01% | -37.23% | +187.04% | +5.26% | -21.46% | +10.05% | -8.19% | -56.43% | +0.86% | +228.36% | -12.42% | -6.86% | -6.33% | n/a |